Literature DB >> 551508

The complement system in host defense and inflammation.

M M Frank.   

Abstract

In this discussion I have reviewed the major role of complement in host defense and inflammation. In addition, I have discussed dificiency states. Although these are rare, their clinical signs and symptoms can be predicted, at least in part, on the basis of our current understanding of the biological activities of complement and the various pathways of complement activation. This is not to say that complement plays no role in a wide variety of other illnesses. However, when complement plays a role in an illness, often this is not because it is functioning in an aberrant fashion. The usual situation is that complement is being activated and is serving its normal function in causing inflammation and damage to tissues under abnormal circumstances. Thus, for example, circulating antigen complexes may be deposited in the kidney, activate complement, and mediate tissue inflammation. In this case, complement is functioning normally but is being activated under abnormal circumstances. The same type of analysis can be made for many diseases of many different organ systems. At present, we have no drugs that are effective in humans in controlling the activation of complement and complement-mediated inflammation. We have not yet even established whether local variations in the activity of complement may affect the course of a clinical infection, but there is certainly strongly suggestive evidence to support this idea. It should be clear that under certain circumstances complement may well be a major factor in controlling the course of an infection. The near future should bring a vast expansion in our understanding of how complement contributes to specific clinical illnesses and to the defense of the host against specific microorganisms.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 551508     DOI: 10.1093/clinids/1.3.483

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  17 in total

1.  Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis.

Authors:  K W Mollison; W Mandecki; E R Zuiderweg; L Fayer; T A Fey; R A Krause; R G Conway; L Miller; R P Edalji; M A Shallcross
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

2.  Ontogeny of the third component of complement of Japanese quails.

Authors:  C Kai; Y Yoshikawa; K Yamanouchi; H Okada; S Morikawa
Journal:  Immunology       Date:  1985-03       Impact factor: 7.397

3.  Serum IgA: modulation of complement activation and induction of susceptibility to bacterial dissemination.

Authors:  J M Griffiss
Journal:  Infection       Date:  1982       Impact factor: 3.553

4.  A possible role of Eubacterium and Peptostreptococcus species in the aetiology of Crohn's disease.

Authors:  J P van de Merwe; G J Mol
Journal:  Antonie Van Leeuwenhoek       Date:  1980       Impact factor: 2.271

5.  Role of capsule and O antigen in resistance of Klebsiella pneumoniae to serum bactericidal activity.

Authors:  J M Tomás; V J Benedí; B Ciurana; J Jofre
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

6.  Enhanced endotoxin clearance in reversed Eck fistula rats during a tolerant stage.

Authors:  Y Yamaguchi; K Mori; H Gans; M Akagi
Journal:  Jpn J Surg       Date:  1986-05

7.  Role of surface components in serum resistance of virulent Aeromonas salmonicida.

Authors:  C B Munn; E E Ishiguro; W W Kay; T J Trust
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

8.  Serum resistance and hemagglutination ability of marine vibrios pathogenic for fish.

Authors:  T J Trust; I D Courtice; A G Khouri; J H Crosa; M H Schiewe
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

9.  Activation of the alternative complement pathway by Sporothrix schenckii.

Authors:  E N Scott; H G Muchmore; D P Fine
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

10.  Virulence factors of Haemophilus ducreyi.

Authors:  J A Odumeru; G M Wiseman; A R Ronald
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.